Recalibrating Pharma after the GST Overhaul

India’s Goods and Services Tax (GST) regime, launched in July 2017, has steadily evolved to simplify tax administration and align fiscal priorities across governments. Since its rollout, the GST regime has undergone continuous refinement, reflecting the evolving needs of the economy and the imperative to reduce litigation and enhance fiscal coordination between the Centre and the states.

At the core of this transformation is the GST Council—India’s apex constitutional authority for indirect tax governance, which has consistently driven reforms through consensus-based decision-making. The 56th GST Council meeting, held on 4 September, 2025, marked a significant milestone in this journey. Focused on rationalising rates and easing compliance, the Council introduced targeted reforms—particularly benefiting the pharmaceutical and medical device sectors. These changes reflect the Council’s ongoing commitment to create a more efficient, transparent and responsive tax framework tailored to the economy’s current needs.

The reform opens up an opportunity for the pharmaceutical and medical device industry to accelerate solutions to some of India’s biggest healthcare priorities, making care more affordable, expanding access to essential medicines and diagnostics, and improving insurance reach. With the headroom created by tax reductions, the industry can invest in innovation, strengthen distribution networks, and advance preventive health solutions–steps that will help lower costs for patients while supporting a more accessible and inclusive healthcare system.

Key tax revisions

Lower GST on medicines and devices directly reduces treatment costs and enhances access to care. It also improves the affordability of insurance packages, paving the way for broader health coverage.

The most notable change is the complete waiver of GST—from 12 percent to nil—on 33 critical life-saving drugs. Additionally, GST has been reduced from five percent to nil on three essential medicines used in the treatment of cancer, rare diseases and other severe chronic conditions. These reductions are aimed at improving affordability and access to essential healthcare.

Beyond life-saving drugs, the GST on all other pharmaceutical products has been lowered from 12 percent to five percent. Medical apparatus and devices used in surgical, dental, veterinary and analytical procedures have seen a significant rate cut from 18 percent to five percent. Similarly, medical consumables such as wadding gauze, bandages, diagnostic kits, reagents and blood glucose monitoring systems (glucometers) now attract only five percent GST, down from 12 percent. Job work services related to pharmaceutical manufacturing have also been reduced from 12 percent to five percent, easing cost pressures across the supply chain.

Strategic implications and the path forward

This sweeping reform presents a unique opportunity for pharmaceutical and medical device manufacturers to recalibrate their operations and drive long-term value. To fully leverage the benefits, companies must adopt a holistic strategy encompassing pricing, tax optimisation, supply chain efficiency, innovation and stakeholder engagement.

• Recalibrating pricing and margins: With the reduction in GST rates, companies must reassess Maximum Retail Prices (MRPs) to reflect the lower tax burden while preserving profitability. Transparent communication of these price adjustments through targeted marketing campaigns can reinforce the social impact and enhance brand credibility.
• Maximising Input Tax Credit (ITC): To mitigate the effects of inverted duty structures, businesses should promptly file provisional refund claims and strengthen ITC tracking mechanisms. Implementing dedicated software and conducting regular reconciliations will ensure accuracy, compliance and improved cash flow management.
• Rethinking supply chain and outsourcing: The revised tax rates necessitate a fresh evaluation of outsourcing arrangements. Renegotiating contracts with job work partners under the new five percent GST slab can yield cost efficiencies. Additionally, optimising logistics and warehousing strategies to capitalise on reduced tax incidence will enhance operational agility and reduce overheads.
• Investing in R&D and portfolio expansion: A portion of the tax savings should be strategically reinvested into research and development, particularly in the creation of affordable diagnostic tools and chronic-care solutions. Accelerating innovation in product categories that now fall under exempt or nil-rated GST brackets can strengthen market positioning and expand access to care.
• Engaging stakeholders proactively: Collaboration with regulatory bodies such as the National Pharmaceutical Pricing Authority (NPPA) is essential to update MRPs in line with new tax norms. Equally important is the training of distributors and retailers to ensure seamless adoption of revised invoicing and compliance protocols.

Transition planning: Ensuring seamless implementation

To navigate this transition effectively, organisations must deploy a comprehensive strategy across inventory management, procurement and digital systems:

• Inventory audit and relabeling: Existing stock at depots and distribution points should undergo a thorough audit, followed by relabeling to reflect updated HSN codes and MRPs. All changes must be documented in ERP systems to maintain traceability and regulatory compliance.
• Optimised stock transfers: For new dispatches, prioritising inventory movement using FIFO principles and consumption-based logic will help prevent ITC accumulation. Procurement strategies should be realigned to favour vendors offering favourable tax positions and flexible payment terms.
• Revised valuation and system readiness: Inventory valuation methods must be updated to incorporate revised tax rates, relabeling costs and potential write-downs. ERP platforms, billing systems and supply chain workflows should be reconfigured to support the new tax regime, enabling automated compliance checks and real-time tracking.

Turning reform into opportunity

While the pharmaceutical sector must address the challenge of ITC reversals on exempt product lines—which could impact working capital, if not managed efficiently—patients and insurers stand to benefit significantly.

To convert this tax relief into a strategic advantage, manufacturers must realign their pricing models, tax planning, supply chain operations, digital infrastructure and stakeholder engagement. With a compressed timeline for implementation, early diagnostics and structured transition planning are critical to ensure compliance, protect profitability and preserve customer trust.

Organisations that embrace these reforms as a springboard for modernisation will be best positioned for sustainable growth in India’s evolving tax ecosystem—and for leading the charge towards more affordable and accessible healthcare.

This article first appeared in the Pharma Industrial India on 15 September 2025. 

Learn more about how our Pharma, bio tech & life sciences services can help you

Visit the page